Passage Bio reports positive Phase 1/2 trial results for PBFT02 in frontotemporal dementia, with planned protocol amendments for safety optimization. Passage Bio, Inc. announced positive results from ...
SAN FRANCISCO — Frontotemporal dementia (FTD) typically strikes adults in their 40s to 60s, often when they’re at the peak of their careers and family responsibilities. Unlike Alzheimer’s disease, ...
LONDON--(BUSINESS WIRE)--AviadoBio, a pioneering gene therapy company dedicated to developing and delivering potentially transformative medicines for neurodegenerative disorders, today announced that ...